LUNG CANCER, NON-SMALL CELL

This study is comparing a new two-drug combination (belrestotug plus dostarlimab) against the current standard treatment (pembrolizumab) for people with advanced non-small cell lung cancer who haven't had prior treatment. The goal is to see if the new combination is safer and mor…

This study compares three established treatments for small lung tumors: surgery, targeted radiation, and a minimally invasive procedure that uses heat or cold to destroy the tumor. Researchers are tracking about 68 patients for two years to see which treatment best controls the c…

This study is testing new combinations of immunotherapy drugs for people with advanced non-small cell lung cancer who haven't had any prior treatment. It focuses on patients whose tumors have high levels of a protein called PD-L1. The main goal is to see how safe these drug combi…

This study is for people with advanced non-small cell lung cancer that has worsened despite standard immunotherapy and chemotherapy. It compares three treatment approaches to see which helps patients live longer: standard chemotherapy alone, chemotherapy plus one immunotherapy dr…

This study is testing whether adding the drug niraparib to standard pembrolizumab maintenance therapy helps people with advanced non-small cell lung cancer live longer without their cancer getting worse. It involves 666 adults whose cancer stabilized or shrank after initial chemo…

This study is testing whether providing medically tailored meals and nutrition counseling to vulnerable lung cancer patients can help them feel better during treatment. It aims to see if this support improves their diet, reduces treatment side effects, and enhances their overall …

This study is testing a 12-week home program designed to help people who have had non-small cell lung cancer and a supportive partner (like a family member or friend) get more active and manage stress. The program includes guided walking, strength training, meditation, and weekly…